NASDAQ: CRME TSX: COM
VANCOUVER, Oct. 31, 2014 /PRNewswire/ - Cardiome Pharma
Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report
financial results for the third quarter ended September 30, 2014 on the morning of Friday, November 7, 2014. Cardiome will hold a
conference call and webcast at 8:00
a.m. Eastern (5:00 a.m.
Pacific) on that day to discuss the results.
To access the conference call, please dial 416-764-8688
or 888-390-0546 and use conference ID 37710827. The webcast
can be accessed through Cardiome's website at www.cardiome.com.
Webcast and telephone replays of the conference call will be
available approximately two hours after the completion of the call
through December 06, 2014. Please
dial 416-764-8677 or 888-390-0541 and enter code 710827# to access
the replay.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a
specialty pharmaceutical company dedicated to the development and
commercialization of cardiovascular therapies that will improve the
quality of life and health of patients suffering from heart
disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in
adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa
inhibitor indicated for use in patients with acute coronary
syndrome.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
SOURCE Cardiome Pharma Corp.